Patents by Inventor Benjamin E. Blass

Benjamin E. Blass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the sigma-2 receptor and their method of use
    Patent number: 12577251
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: March 17, 2026
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20260070907
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 14, 2025
    Publication date: March 12, 2026
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20260070908
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 14, 2025
    Publication date: March 12, 2026
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
    Patent number: 12559494
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein A is selected from a group consisting of:
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 24, 2026
    Assignees: Temple University-Of The Commonwealth System of Higher Education, Praeventix, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 12503458
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: December 23, 2025
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20250282790
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 20, 2025
    Publication date: September 11, 2025
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
    Patent number: 12338247
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: June 24, 2025
    Assignees: Temple University-Of The Commonwealth System of Higher Education, Praeventix, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
    Patent number: 12338245
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: June 24, 2025
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 12269809
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: April 8, 2025
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20240425487
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 19, 2023
    Publication date: December 26, 2024
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE
    Publication number: 20240300954
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: October 11, 2023
    Publication date: September 12, 2024
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20240300953
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2023
    Publication date: September 12, 2024
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 11897870
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 13, 2024
    Assignee: Temple University-Of The Commonwealth System Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Modulators of the sigma-2 receptor and their method of use
    Patent number: 11820774
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
    Patent number: 11807642
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: November 7, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
    Publication number: 20230202993
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: September 8, 2022
    Publication date: June 29, 2023
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20230112888
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 13, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20230002383
    Abstract: Described herein are new, selective modulators of the 5-HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT7 modulator.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20220348581
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 3, 2021
    Publication date: November 3, 2022
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20220306629
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 29, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin